Opinion|Videos|July 12, 2024
Key Takeaways on Recent Data from PERSEUS
Author(s)Cesar Rodriguez, MD, Frits van Rhee, MD, PhD
Frits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are your key takeaways on findings from the PERSEUS trial?
- What are some remaining unanswered questions from this trial?
- What will be important to evaluate in future analyses and research?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
2
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
3
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
4
Training, Invasiveness, and Workload Behind Falling Prostate Brachytherapy Use
5